drugset
drugset / Trial / NCT06738277

This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

NCT06738277 ↗

Phase 1 Completed 186 enrolled Biocon Biologics UK Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab 1200 -prefilled syringe (PFS).

Timeline

Start
2025-01-09
Primary completion
2025-07-12
Completion
2025-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bmab 1200 Unknown 45 mg Subcutaneous

Indications

psoriasis